Products Categories
CAS No.: | 56238-63-2 |
---|---|
Name: | Cefuroxime sodium |
Molecular Structure: | |
Formula: | C16H15N4NaO8S |
Molecular Weight: | 446.38 . |
Synonyms: | 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,3-[[(aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-furanyl(methoxyimino)acetyl]amino]-8-oxo-,monosodium salt, (6R,7R)- (9CI);5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,3-[[(aminocarbonyl)oxy]methyl]-7-[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-,monosodium salt, [6R-[6a,7b(Z)]]-;640/359;Biociclin;Bioxima;Cefamar;Cefumax;Cefurex;Cefurin;Curocef;Curoxim;Duxima;Ipacef;Kefurox;Lampsporin;Medoxim;Novocef;Spectrazol;Ultroxim;Zinacef; |
EINECS: | 260-073-1 |
Melting Point: | 240-245 °C(dec) |
Solubility: | Freely soluble in water |
Appearance: | White Crystalline Solid |
Hazard Symbols: | Xn |
Risk Codes: | 42/43-36/37/38-20/21/22 |
Safety: | 22-36/37-45-36-26 |
PSA: | 201.89000 |
LogP: | -0.84160 |
Molecular Structure of Cefuroxime sodium (CAS NO.56238-63-2):
IUPAC Name: Sodium(6R,7R)-3-(carbamoyloxymethyl)-7-[[(2E)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
Molecular Weight: 446.36707 [g/mol]
Molecular Formula: C16H15N4NaO8S
H-Bond Donor: 2
H-Bond Acceptor: 9
EINECS: 260-073-1
Appearance: White Crystalline Solid
Melting Point: 240-245 °C(dec)
storage temp.: 2-8 °C
Classification Code: Antibacterial; Antibiotics; Drug / Therapeutic Agent; Reproductive Effect
Product Categories: API; Intermediates & Fine Chemicals; Pharmaceuticals; CA - CGForensic and Veterinary Standards; Alphabetic; C; Chemical Structure; Drugs & Metabolites; Neat CompoundsDrugs of Abuse; Others
SMILES: [Na+].O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)\c3occc3)COC(=O)N)C([O-])=O
InChI: InChI=1/C16H16N4O8S.Na/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20;/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24);/q;+1/p-1/b19-9+;/t10-,14-;/m1./s1
InChIKey: URDOHUPGIOGTKV-DHJHYLGLBI
Cefuroxime sodium (CAS NO.56238-63-2) is prescribed in the treatment of lower respiratory tract, urinary tract, skin, and gonococcal infections; bacterial septicemia; and meningitis and for the prevention of postoperative infections.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD50 | intravenous | > 1500mg/kg (1500mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 13, Pg. 349, 1982. | |
mouse | LD50 | intramuscular | > 2gm/kg (2000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 261, 1982. | |
mouse | LD50 | intraperitoneal | > 10gm/kg (10000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 261, 1982. | |
mouse | LD50 | intravenous | 10400mg/kg (10400mg/kg) | Toxicology. Vol. 13, Pg. 1, 1979. | |
mouse | LD50 | oral | > 10gm/kg (10000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 261, 1982. | |
mouse | LD50 | subcutaneous | > 10gm/kg (10000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 261, 1982. | |
rabbit | LD50 | intramuscular | > 300mg/kg (300mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 261, 1982. | |
rabbit | LD50 | intravenous | > 1500mg/kg (1500mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 261, 1982. | |
rat | LD50 | intramuscular | > 2gm/kg (2000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 261, 1982. | |
rat | LD50 | intraperitoneal | 10gm/kg (10000mg/kg) | KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Chemotherapy Vol. 27(Suppl, |
rat | LD50 | intravenous | 4gm/kg (4000mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Toxicology. Vol. 13, Pg. 1, 1979. |
rat | LD50 | oral | > 10gm/kg (10000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 261, 1982. | |
rat | LD50 | subcutaneous | > 10gm/kg (10000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 261, 1982. |
Safety Information of Cefuroxime sodium (CAS NO.56238-63-2):
Hazard Codes: Xn
Risk Statements: 42/43-36/37/38-20/21/22
R42/43:May cause sensitization by inhalation and skin contact.
R36/37/38:Irritating to eyes, respiratory system and skin.
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed.
Safety Statements: 22-36/37-45-36-26
S22:Do not breathe dust.
S36/37:Wear suitable protective clothing and gloves.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S36:Wear suitable protective clothing.
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
WGK Germany: 2
RTECS: XI0330000
Moderately toxic by intravenous route. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of SOx, NOx, and Na2O.
Cefuroxime sodium (CAS NO.56238-63-2), its Synonyms are 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-furanyl(methoxyimino)acetyl)amino)-8-oxo-, monosodium salt (6R-(6alpha,7beta(Z)))- ; Anaptivan ; Biociclin ; Bioxima ; Cefofix ; Cefumax ; Cefurex ; Cefuroxim AJ ; Cefuroxim Fresenius ; Cefuroxim Genericsn ; Cefuroxim Hexal ; Cefuroxime and dextrose in duplex container ; Cefuroxime for Injection and Dextrose for Injection in Duplex Container ; Sodium (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), carbamate (ester) ; Sodium cefuroxime ; Spectrazolr .